TDP-43 as a Fluid Biomarker in Amyotrophic Lateral Sclerosis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder characterized by the death of both upper and lower motor neurons in the brain, brainstem, and spinal cord. In approximately 95% of cases, ALS is associated with the nuclear-cytoplasmic mislocalization and aggregation of TAR DNA-binding protein 43 (TDP-43). The diagnosis of ALS is based solely on clinical assessments, including neurological examinations and electromyography studies, and currently, there is no reliable biomarker for diagnosing ALS using antemortem tissues. Additionally, while TDP-43 positron emission tomography ligands are being investigated, they are not yet widely available for assessing brain TDP-43 pathology. Therefore, a robust fluid biomarker that reflects pathological TDP-43 accumulation in the central nervous system is essential for confirming an ALS diagnosis. In this context, we provide a comprehensive summary of the current status of fluid biomarker development, focusing on TDP-43 pathology, and discuss the existing limitations as well as future directions for ALS biomarker discovery.
Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder characterized by the death of both upper and lower motor neurons in the brain, brainstem, and spinal cord. In approximately 95% of cases, ALS is associated with the nuclear-cytoplasmic mislocalization and aggregation of TAR DNA-binding protein 43 (TDP-43). The diagnosis of ALS is based solely on clinical assessments, including neurological examinations and electromyography studies, and currently, there is no reliable biomarker for diagnosing ALS using antemortem tissues. Additionally, while TDP-43 positron emission tomography ligands are being investigated, they are not yet widely available for assessing brain TDP-43 pathology. Therefore, a robust fluid biomarker that reflects pathological TDP-43 accumulation in the central nervous system is essential for confirming an ALS diagnosis. In this context, we provide a comprehensive summary of the current status of fluid biomarker development, focusing on TDP-43 pathology, and discuss the existing limitations as well as future directions for ALS biomarker discovery.
참고문헌 (20)
- Hardiman O, "Amyotrophic lateral sclerosis", Nat Rev Dis Primers, 3, pp.17071~ (2017)
- Tziortzouda P, "Triad of TDP43 control in neurodegeneration : autoregulation, localization and aggregation", Nat Rev Neurosci, 22, pp.197~208 (2021)
- Meneses A, "TDP-43 pathology in Alzheimer's disease", Mol Neurodegener, 16, pp.84~ (2021)
- Nelson PT, "Limbic-predominant age-related TDP-43 encephalopathy(LATE) : consensus working group report", Brain, 142, pp.1503~1527 (2019)
- Weihl CC, "TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia", J Neurol Neurosurg Psychiatry, 79, pp.1186~1189 (2008)
- Brooks BR, "World Federation of Neurology Research Group on Motor Neuron Diseases : El Escorial revisited : revised criteria for the diagnosis of amyotrophic lateral sclerosis", Amyotroph Lateral Scler Other Motor Neuron Disord, 1, pp.293~299 (2000)
- de Carvalho M, "Electrodiagnostic criteria for diagnosis of ALS", Clin Neurophysiol, 119, pp.497~503 (2008)
- Shefner JM, "A proposal for new diagnostic criteria for ALS", Clin Neurophysiol, 131, pp.1975~1978 (2020)
- Seredenina T, "Discovery and optimization of the first-in-class TDP-43 PET tracer", Alzheimers Dement, 19, pp.e075525~ (2023)
- Steinacker P, "TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis", Arch Neurol, 65, pp.1481~1487 (2008)
- Kasai T, "Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis", Acta Neuropathol, 117, pp.55~62 (2009)
- Noto Y, "Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis : specificity, sensitivity, and a possible prognostic value", Amyotroph Lateral Scler, 12, pp.140~143 (2011)
- Verstraete E, "TDP-43 plasma levels are higher in amyotrophic lateral sclerosis", Amyotroph Lateral Scler, 13, pp.446~451 (2012)
- Kasai T, "Combined use of CSF NfL and CSF TDP-43 improves diagnostic performance in ALS", Ann Clin Transl Neurol, 6, pp.2489~2502 (2019)
- Ren Y, "TDP-43 and phosphorylated TDP-43 levels in paired plasma and CSF samples in amyotrophic lateral sclerosis", Front Neurol, 12, pp.663637~ (2021)
- Hishizawa M, "TDP-43 levels are higher in platelets from patients with sporadic amyotrophic lateral sclerosis than in healthy controls", Neurochem Int, 124, pp.41~45 (2019)
- Candelise N, "Towards an improved early diagnosis of neurodegenerative diseases : the emerging role of in vitro conversion assays for protein amyloids", Acta Neuropathol Commun, 8, pp.117~ (2020)
- Scialò C, "et al : TDP-43 real-time quaking induced conversion reaction optimization and detection of seeding activity in CSF of amyotrophic lateral sclerosis and frontotemporal dementia patients", Brain Commun, 2, pp.fcaa142~ (2020)
- Mehta PR, "The era of cryptic exons : implications for ALS-FTD", Mol Neurodegener, 18, pp.16~ (2023)
- Irwin KE, "A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD", Nat Med, 30, pp.382~393 (2024)